How does HIV infection induce dementia? One mechanism may involve viral interference with neuron generation in the brain, and this mechanism might one day be targeted by a newly developed class of drugs, according to a study published in the July 15, 2004 issue of The Journal of Infectious Diseases.
Researchers Mitchell D. Krathwohl and Jodi L. Kaiser, of the University of Minnesota, report that HIV uses proteins on its outer coat to bind to receptors on the cellular precursors of neurons, called neural progenitor cells, which then receive an off signal from the virus that prevents them from differentiating into neurons. The resulting increase in the number of resting progenitor cells and decrease in the number of newly differentiated neurons may underlie the impaired cognition and memory loss of AIDS dementia complex.
The Minnesota investigators study was based on recent findings showing that neural progenitor cells capable of differentiating into neurons proliferate in adults, not just in fetuses as previously thought; that the area of the brain known as the hippocampus is rich in neural progenitor cells; and that such cells can be forced into quiescence by chemokines, molecules that deliver signals to cells by attaching themselves to specific cell-surface receptors. Because HIV is known to bind to chemokine receptors and send signals through them, the investigators hypothesized that the virus may use chemokines to cripple neuron generation.
Krathwohl and Kaiser first demonstrated that certain HIV coat proteins using certain chemokine receptors inhibited neural progenitor cells in culture, and that the effect was mediated by the receptors. They then showed that the coat proteins inhibited a metabolic step necessary for neural progenitor cell proliferation; indirect evidence suggested that this occurred via signaling through chemokine receptors. The investigators next found that cerebral spinal fluid from patients with AIDS dementia also inhibited neural progenitor cell proliferation. They then showed that progenitor cell numbers were reduced in hippocampal tissue obtained at autopsy from demented patients with HIV infection compared to that from non-demented patients with or without the infection.
Finally, the researchers examined a certain class of proteins, called apolipoproteins, that help transport fat in the bloodstream. The study found that apolipoprotein E3 blocked HIV coat protein inhibition of neural progenitor cell proliferation but the E4 protein did not, suggesting a possible explanation for the association between AIDS dementia and the E4 genotype.
The investigators noted that the ability of HIV to inhibit neuron proliferation by chemokine signaling at the cell surface represented a phenomenon distinct from entry into cell, the mechanism by which viruses are conventionally thought to exert pathogenic effects.
Commenting on the Minnesota study in an accompanying editorial, Aimee Kao and Richard Price, of the University of California, San Francisco, characterized the work as intriguing but cautioned that more experimental work with cell and animal models is needed to confirm these findings and define their molecular basis with precision. They pointed out, however, that the recent development of drugs that interfere with HIV-chemokine receptor binding may afford a special opportunity to test hypotheses of chemoreceptor-mediated brain injury, and that such agents may even have potential for mitigating AIDS dementia complex.
Source: Infectious Diseases Society of America (IDSA)
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.